Xtant 10-Q Details Cash Drain to $7.8M, Two Covenant Waivers and Unremediated Material Weakness
XTNT is trading near its 52-week low of $0.26 (0.1% above the low) on light trading volume (0.1× avg).
Summary
Xtant's Q3 10-Q confirms the miss and strategic review already announced, and shows cash down to $7.8M against $21M of debt, two 2026 covenant waivers from MidCap, and an unremediated material weakness.
Key Events · Earnings and Guidance · XTNT
-
Q3 Revenue Falls 27%
Revenue was $24.3M versus $33.3M a year earlier, driven by the absence of $5.4M of divested Coflex/CoFix and international hardware sales and $5.5M of prior-year license revenue, partly offset by $2.2M of HEMOBLAST sales.
-
Losses Widen, Gross Margin Compresses
Net loss was $3.6M (-$0.03 per share) versus $1.3M of net income a year earlier; gross margin fell to 56.3% from 66.1%, with 670 basis points of the drop from lost license revenue.
-
Cash Falls to $7.8M Against $21M Debt
Cash and equivalents dropped to $7.8M from $17.1M at December 31, 2025, while $9.3M of term debt and $11.8M drawn on the revolver leave only $2.1M of revolver availability.
-
Two Covenant Waivers From MidCap
Amendments in March and August 2026 eliminated minimum net revenue covenant tests the company would otherwise have failed, in exchange for raising quarterly term principal payments to $1.1M in Q4 2026 and $1.2M thereafter.
Analysis · XTNT · Industrial Applications And Services
The headline numbers — a 27% revenue decline, a $3.6M quarterly loss, withdrawn 2026 guidance and a Board strategic review — were already released in today's 8-K. What the 10-Q adds is the balance-sheet reality behind that review: cash fell to $7.8M from $17.1M at year-end, and the company carries $9.3M of term debt plus $11.8M drawn on its revolver with only $2.1M of remaining availability. Twice this year (March and August) MidCap had to amend the credit agreement to waive a minimum revenue covenant the company would otherwise have breached, and the price was higher quarterly principal payments — $1.1M in Q4 2026 and $1.2M per quarter from 2027. Management says liquidity lasts through at least November 2027, but that assumes sales improve and expenses fall; any shortfall means another raise, more dilution, or a worse outcome. The previously reported inventory-valuation material weakness is still unremediated, so disclosure controls remain ineffective. With the stock near its 52-week low, the strategic review is now the main thing standing between the company and a dilutive or distressed financing.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XTNT was trading at $0.26 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $38.1M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.